P
Philipp Schommers
Researcher at University of Cologne
Publications - 52
Citations - 2277
Philipp Schommers is an academic researcher from University of Cologne. The author has contributed to research in topics: Antibody & Medicine. The author has an hindex of 19, co-authored 37 publications receiving 1009 citations. Previous affiliations of Philipp Schommers include Heinrich Pette Institute & Innsbruck Medical University.
Papers
More filters
Journal ArticleDOI
Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study.
Max Augustin,Philipp Schommers,Melanie Stecher,Felix Dewald,Lutz Gieselmann,Henning Gruell,Carola Horn,Kanika Vanshylla,Veronica Di Cristanziano,Luise Osebold,Maria Roventa,Toqeer Riaz,Nikolai Tschernoster,Janine Altmueller,Leonard Rose,Susanne Salomon,Vanessa Priesner,Jan Christoffer Luers,Christian Albus,Stephan Rosenkranz,Birgit S. Gathof,Gerd Fätkenheuer,Michael Hallek,Florian Klein,Isabelle Suárez,Clara Lehmann +25 more
TL;DR: The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS).
Journal ArticleDOI
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients.
Christoph Kreer,Matthias Zehner,Timm Weber,Meryem S. Ercanoglu,Lutz Gieselmann,Cornelius Rohde,Sandro Halwe,M. Korenkov,Philipp Schommers,Kanika Vanshylla,Veronica Di Cristanziano,Hanna Janicki,Reinhild Brinker,Artem Ashurov,Verena Krähling,Alexandra Kupke,Hadas Cohen-Dvashi,Manuel Koch,Jan Mathis Eckert,Simone Lederer,Nico Pfeifer,Timo Wolf,Maria J G T Vehreschild,Clemens M. Wendtner,Ron Diskin,Henning Gruell,Stephan Becker,Florian Klein +27 more
TL;DR: It is demonstrated that SARS-CoV-2-neutralizing antibodies are readily generated from a diverse pool of precursors, fostering hope for rapid induction of a protective immune response upon vaccination.
Journal ArticleDOI
Swarm Learning for decentralized and confidential clinical machine learning.
Stefanie Warnat-Herresthal,Hartmut Schultze,K. Shastry,Sathyanarayanan Manamohan,Saikat Mukherjee,Vishesh Garg,Ravi Sarveswara,Kristian Händler,Peter Pickkers,N. Ahmad Aziz,Sofia Ktena,Florian Tran,Michael Bitzer,Stephan Ossowski,Nicolas Casadei,Christian Herr,Daniel Petersheim,Uta Behrends,Fabian Kern,Tobias Fehlmann,Philipp Schommers,Clara Lehmann,Max Augustin,Jan Rybniker,Janine Altmüller,Neha Mishra,Joana P. Bernardes,Benjamin Krämer,Lorenzo Bonaguro,Jonas Schulte-Schrepping,Elena De Domenico,Christian Siever,Michael Kraut,Milind Desai,Bruno Monnet,Maria Saridaki,Charles Siegel,Anna Drews,Melanie Nuesch-Germano,Heidi Theis,Jan Heyckendorf,Stefan Schreiber,Sarah Kim-Hellmuth,Jacob Nattermann,Dirk Skowasch,Ingo Kurth,Andreas Keller,Andreas Keller,Robert Bals,Peter Nürnberg,Olaf Rieß +50 more
TL;DR: Wang et al. as mentioned in this paper proposed Swarm Learning, a decentralized machine learning approach that unifies edge computing, blockchain-based peer-to-peer networking and coordination while maintaining confidentiality without the need for a central coordinator.
Journal ArticleDOI
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans.
Kanika Vanshylla,Veronica Di Cristanziano,Franziska Kleipass,Felix Dewald,Philipp Schommers,Lutz Gieselmann,Henning Gruell,Maike Schlotz,Meryem S. Ercanoglu,Ricarda Stumpf,Petra Mayer,Matthias Zehner,Eva Heger,Wibke Johannis,Carola Horn,Isabelle Suárez,Norma Jung,Susanne Salomon,Kirsten Alexandra Eberhardt,Kirsten Alexandra Eberhardt,Birgit Gathof,Gerd Fätkenheuer,Nico Pfeifer,Ralf Eggeling,Max Augustin,Clara Lehmann,Florian Klein +26 more
TL;DR: In this article, the authors evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19 and found that approximately 3% of individuals demonstrated exceptional SARSCoV2 neutralization, with these "elite neutralizers" also possessing SARS CoV-1 cross-neutralizing IgG.
Journal ArticleDOI
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody.
Philipp Schommers,Henning Gruell,Morgan E. Abernathy,My-Kim Tran,Adam S. Dingens,Harry B. Gristick,Christopher O. Barnes,Till Schoofs,Maike Schlotz,Kanika Vanshylla,Christoph Kreer,Daniela Weiland,Udo Holtick,Christof Scheid,Markus Valter,Marit J. van Gils,Rogier W. Sanders,Rogier W. Sanders,Jörg J. Vehreschild,Oliver A. Cornely,Clara Lehmann,Gerd Fätkenheuer,Michael S. Seaman,Jesse D. Bloom,Jesse D. Bloom,Pamela J. Bjorkman,Florian Klein +26 more
TL;DR: 1-18 is described, a new VH1-46-encoded CD4 binding site (CD4bs) bNAb with outstanding breadth and potency and the ability of 1-18 to effectively restrict HIV-1 escape pathways provides a new option to successfully prevent and treat HIV- 1 infection.